KR101063663B1 - 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 - Google Patents

피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 Download PDF

Info

Publication number
KR101063663B1
KR101063663B1 KR1020077020924A KR20077020924A KR101063663B1 KR 101063663 B1 KR101063663 B1 KR 101063663B1 KR 1020077020924 A KR1020077020924 A KR 1020077020924A KR 20077020924 A KR20077020924 A KR 20077020924A KR 101063663 B1 KR101063663 B1 KR 101063663B1
Authority
KR
South Korea
Prior art keywords
leu
gly
ala
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020077020924A
Other languages
English (en)
Korean (ko)
Other versions
KR20070107122A (ko
Inventor
다까히로 이시이
다까시 수가네
준 마에다
후미에 나라자끼
아끼오 가께후다
겐따로 사또
다쯔히사 다까하시
다까또시 가나야마
치까시 사이또
조따로 스즈끼
치사또 가나이
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20070107122A publication Critical patent/KR20070107122A/ko
Application granted granted Critical
Publication of KR101063663B1 publication Critical patent/KR101063663B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020077020924A 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 Active KR101063663B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2005-00040197 2005-02-17
JP2005040197 2005-02-17
JP2005303065 2005-10-18
JPJP-P-2005-00303065 2005-10-18
PCT/JP2006/302698 WO2006088075A1 (ja) 2005-02-17 2006-02-16 ピリジル 非芳香族含窒素ヘテロ環－１－カルボン酸エステル誘導体

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020097011569A Division KR101065979B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체
KR1020097011570A Division KR101063585B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체

Publications (2)

Publication Number Publication Date
KR20070107122A KR20070107122A (ko) 2007-11-06
KR101063663B1 true KR101063663B1 (ko) 2011-09-07

Family

ID=36916476

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077020924A Active KR101063663B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
KR1020097011570A Expired - Fee Related KR101063585B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체
KR1020097011569A Expired - Fee Related KR101065979B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020097011570A Expired - Fee Related KR101063585B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체
KR1020097011569A Expired - Fee Related KR101065979B1 (ko) 2005-02-17 2006-02-16 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르 유도체

Country Status (20)

Country Link
US (3) US7919495B2 (enExample)
EP (2) EP1849773B1 (enExample)
JP (1) JP4702361B2 (enExample)
KR (3) KR101063663B1 (enExample)
CN (1) CN101160287B (enExample)
AU (3) AU2006215080B2 (enExample)
BR (1) BRPI0608205B8 (enExample)
CA (1) CA2598294C (enExample)
CY (2) CY1114709T1 (enExample)
DK (2) DK2607362T3 (enExample)
ES (2) ES2528674T3 (enExample)
IL (1) IL184998A (enExample)
MX (1) MX2007010076A (enExample)
NO (1) NO20074697L (enExample)
PL (2) PL2607362T3 (enExample)
PT (2) PT1849773E (enExample)
RU (3) RU2408580C2 (enExample)
SI (2) SI2607362T1 (enExample)
TW (3) TWI385164B (enExample)
WO (1) WO2006088075A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
JP2008545010A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
EP1910290A2 (en) * 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2007098086A2 (en) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
WO2008023720A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
AP2780A (en) 2006-10-18 2013-09-30 Pfizer Prod Inc Biaryl ether urea compounds
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
TW201446748A (zh) 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
CA2720950A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
TWI434842B (zh) * 2008-07-14 2014-04-21 Astellas Pharma Inc Azole compounds
EP2351749A1 (en) 2008-11-06 2011-08-03 Astellas Pharma Inc. Carbamate compound or salt thereof
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
ME01908B (me) 2009-12-17 2014-12-20 Boehringer Ingelheim Int Novi antagonisti ccr2 receptora i njihova primjena
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
SG182803A1 (en) * 2010-02-05 2012-09-27 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
NZ602110A (en) 2010-02-18 2014-09-26 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JP2013147430A (ja) * 2010-04-28 2013-08-01 Astellas Pharma Inc 夜間頻尿の予防又は治療剤
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
HRP20180543T1 (hr) * 2012-07-24 2018-06-29 Bial-Portela & Ca, S.A. Spojevi uree i njihova upotreba kao inhibitora enzima
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
EP4424683A3 (en) * 2017-03-13 2024-11-06 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
SG10201802129QA (en) * 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
CN111787916B (zh) 2018-01-11 2023-09-05 森陶鲁斯治疗公司 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂
MA53607B1 (fr) 2018-09-13 2025-05-30 Celgene Corporation (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés
WO2020159576A1 (en) * 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
EP4065098A4 (en) 2019-11-29 2023-12-27 Autobahn Therapeutics, Inc. NOVEL THYROMIMETICS
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541109A (ja) 1999-04-01 2002-12-03 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (enExample) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
RO115159B1 (ro) 1995-01-11 1999-11-30 Samjin Pharmaceutical Co., Ltd Derivaţi de piperazină şi compoziţii farmaceutice care îi conţin
CN1152015C (zh) * 1996-06-29 2004-06-02 三进制药株式会社 新哌嗪衍生物及其制造方法
US5870472A (en) 1996-11-12 1999-02-09 General Instrument Corporation Dynamic relocation of the service data channel
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
EA200000768A1 (ru) 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
JP4829449B2 (ja) 1999-07-28 2011-12-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 置換オキソアザヘテロシクリル化合物
AP2001002360A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors.
EP1231212B1 (en) 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
JP2005518377A (ja) 2001-12-14 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ ホルモン感受性リパーゼの活性を低下させるための化合物の使用
JP2003192659A (ja) 2001-12-26 2003-07-09 Bayer Ag フェニル尿素誘導体
WO2003055848A2 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
US6949574B2 (en) 2002-02-08 2005-09-27 Bristol-Myers Squibb Company (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
JP4515911B2 (ja) * 2002-10-07 2010-08-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アナンダミド加水分解の遮断による不安の調節
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004111007A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase
EP1636187A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
EP1636207A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
PL1882684T3 (pl) * 2005-05-19 2015-08-31 Astellas Pharma Inc Pochodna pirolidyny albo jej sól

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541109A (ja) 1999-04-01 2002-12-03 ファイザー・プロダクツ・インク ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン

Also Published As

Publication number Publication date
EP1849773A4 (en) 2011-06-15
ES2528674T3 (es) 2015-02-11
US7919495B2 (en) 2011-04-05
KR20090077855A (ko) 2009-07-15
ES2433290T3 (es) 2013-12-10
CN101160287A (zh) 2008-04-09
TW200940507A (en) 2009-10-01
CY1114709T1 (el) 2016-10-05
DK2607362T3 (en) 2015-01-19
MX2007010076A (es) 2007-10-16
BRPI0608205B1 (pt) 2019-02-05
IL184998A0 (en) 2007-12-03
EP2607362A1 (en) 2013-06-26
EP2607362B1 (en) 2014-12-31
CN101160287B (zh) 2011-08-03
TWI385164B (zh) 2013-02-11
WO2006088075A1 (ja) 2006-08-24
BRPI0608205B8 (pt) 2021-05-25
RU2009121774A (ru) 2010-09-27
US20100009972A1 (en) 2010-01-14
TWI359140B (enExample) 2012-03-01
AU2010202348B2 (en) 2011-07-21
EP1849773B1 (en) 2013-10-16
BRPI0608205A2 (pt) 2009-12-01
US20080306046A1 (en) 2008-12-11
CA2598294C (en) 2011-10-18
RU2007134441A (ru) 2009-03-27
RU2376289C2 (ru) 2009-12-20
PL2607362T3 (pl) 2015-05-29
US7919494B2 (en) 2011-04-05
JP4702361B2 (ja) 2011-06-15
EP1849773A1 (en) 2007-10-31
AU2006215080B2 (en) 2011-03-10
DK1849773T3 (da) 2013-11-04
CY1116348T1 (el) 2017-02-08
KR20090078841A (ko) 2009-07-20
PT2607362E (pt) 2015-03-16
AU2010202347B2 (en) 2011-06-02
IL184998A (en) 2014-11-30
TW200940526A (en) 2009-10-01
RU2408580C2 (ru) 2011-01-10
AU2010202347A1 (en) 2010-07-01
SI2607362T1 (sl) 2015-03-31
JPWO2006088075A1 (ja) 2008-07-03
KR101065979B1 (ko) 2011-09-19
KR20070107122A (ko) 2007-11-06
PT1849773E (pt) 2013-12-04
AU2010202348A1 (en) 2010-07-01
PL1849773T3 (pl) 2014-03-31
CA2598294A1 (en) 2006-08-24
TW200640864A (en) 2006-12-01
KR101063585B1 (ko) 2011-09-07
NO20074697L (no) 2007-11-16
RU2009121775A (ru) 2010-09-27
US20100009971A1 (en) 2010-01-14
RU2408581C2 (ru) 2011-01-10
SI1849773T1 (sl) 2013-12-31
US7915261B2 (en) 2011-03-29
TWI385152B (zh) 2013-02-11
AU2006215080A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
KR101063663B1 (ko) 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
CN108025002B (zh) 含有六元氮杂杂环的δ阿片受体调节化合物、其使用和制备方法
CN101466378A (zh) 用于治疗骨关节炎和骨关节病的哌啶衍生物
HK40069148A (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
HK1254498B (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070913

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080401

Comment text: Request for Examination of Application

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090604

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100315

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101113

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20110728

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110901

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110901

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140825

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140825

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150730

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150730

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160818

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170818

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180816

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200730

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210901

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230822

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20240822

Start annual number: 14

End annual number: 14